Molecular Tumor Board at the Center for Personalized Medicine Tübingen

Last updated: April 18, 2018
Sponsor: University Hospital Tuebingen
Overall Status: Active - Recruiting

Phase

N/A

Condition

Metastatic Cancer

Treatment

N/A

Clinical Study ID

NCT03503149
ZPM-001
  • All Genders

Study Summary

Molecular Tumor Board at the Center for Personalized Medicine

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Given informed consent ("broad consent" of the University Hospital Tübingen)

  • ≥ 18 years of age

  • Clinical indication for a referral to Molecular Tumor Board by the treating physician

Exclusion

Exclusion Criteria:

  • The MTB assists the referring physician with the interpretation and the use of tumormolecular profiling data for deciding on a therapeutic strategy. Therefore, this boardis confined to cancer patients and cannot provide any service for non-cancer patients

Study Design

Total Participants: 1000
Study Start date:
March 01, 2018
Estimated Completion Date:
March 01, 2028

Study Description

Molecular Tumor Board at the Center for Personalized Medicine The study objectives are

  • To ensure a prospective documentation of all patients who are referred to the Molecular Tumor Board in routine clinical care

  • To prospectively ensure the documentation of MTB patients with an emphasis to clinical outcome parameters progression-free survival (PFS), overall survival (OS) and further response assessments (e.g. peripheral immunmonitoring, imaging parameters)

  • To prospectively assess patient-reported outcome of MTB patients

  • To evaluate compliance to MTB suggestions in routine clinical care

Connect with a study center

  • University Hospital Tübingen

    Tübingen, BW 72076
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.